还原响应性纳米基因载体靶向递送miR-148b抑制HuH-7细胞转移侵袭的研究

还原响应性纳米基因载体靶向递送miR-148b抑制HuH-7细胞转移侵袭的研究摘要：本研究旨在探究响应性纳米基因载体靶向递送miR-148b对于人肝癌细胞HuH-7的转移侵袭的抑制作用。经过实验确定，miR-148b在肝癌细胞中明显下调，同时与肝癌细胞的转移和侵袭密切相关。选择LLC-PK1细胞作为对照组，在对LLC-PK1和HuH-7细胞进行细胞毒性实验后，得出响应性纳米基因载体对于HuH-7细胞的细胞毒性较小。通过WesternBlot实验断定，响应性纳米基因载体靶向递送miR-148b显著下调了HuH-7细胞中的MMP2和MMP9的表达，同时抑制了肝癌细胞的转移和侵袭。本研究结果表示，响应性纳米基因载体靶向递送miR-148b可以用于抑制肝癌细胞的转移和侵袭，在临床中将具有广阔的应用前景。

关键词：响应性纳米基因载体；miR-148b；HuH-7细胞；转移；侵袭

Abstract:ThepurposeofthisstudyistoexploretheinhibitoryeffectofresponsenanoscalegenevectortargeteddeliveryofmiR-148bontheinvasionandmetastasisofhumanlivercancercellsHuH-7.AfterexperimentwefoundthatmiR-148bwassignificantlydown-regulatedinlivercancercellsandwascloselyrelatedtothemetastasisandinvasionoflivercancercells.LLC-PK1cellswerechosenasthecontrolgroup.AfterconductingcelltoxicityexperimentsonLLC-PK1andHuH-7cells,itwasconcludedthatresponsenanoscalegenevectorhadlesstoxicitytoHuH-7cells.WesternBlotexperimentsindicatedthatresponsenanoscalegenevectortargeteddeliveryofmiR-148bsignificantlydown-regulatedtheexpressionofMMP2andMMP9inHuH-7cells,andinhibitedtheinvasionandmetastasisoflivercancercells.TheresultsofthisstudyshowthatresponsenanoscalegenevectortargeteddeliveryofmiR-148bcanbeusedtoinhibittheinvasionandmetastasisoflivercancercellsandwillhavebroadapplicationprospectsinclinicalpractice.

Keywords:responsenanoscalegenevector;miR-148b;HuH-7cells;metastasis;invasioLivercancerisoneofthemostcommontypesofcancerworldwideandisoftenassociatedwithpoorprognosisduetoitsinvasiveandmetastaticnature.Therefore,thereisaneedforeffectivetherapiestargetingtheseprocesses.MicroRNAs(miRNAs)haveemergedaspromisingtherapeutictargetsduetotheirabilitytoregulatemultiplegenesinvolvedintumorprogression.

Inthisstudy,wefocusedonmiR-148b,whichhasbeenpreviouslyshowntohaveanti-metastaticeffectsinlivercancer.However,theuseofmiRNAsintherapyislimitedbytheirlowstabilityandbioavailabilityinvivo.Toovercometheselimitations,weutilizedaresponsenanoscalegenevectorthatcantargetlivercancercellsanddelivermiR-148bspecifically.

OurresultsshowedthattargeteddeliveryofmiR-148busingtheresponsenanoscalegenevectorsignificantlydown-regulatedtheexpressionofMMP2andMMP9inHuH-7cells.TheMMPsareknowntobecrucialforinvasionandmetastasisandtheirdownregulationisexpectedtoinhibittheseprocesses.Consistentwiththis,weobservedthattheinvasionandmetastasisofHuH-7cellsweresignificantlyinhibitedfollowingtreatmentwiththeresponsenanoscalegenevectorcarryingmiR-148b.

Takentogether,theseresultssuggestthatresponsenanoscalegenevectortargeteddeliveryofmiR-148bcaneffectivelyinhibittheinvasionandmetastasisoflivercancercells.Assuch,thisapproachhasgreatpotentialforuseinclinicalpracticeasatherapeuticstrategyforlivercancerpatients.However,furtherstudiesareneededtooptimizethedeliveryanddosageofthistherapyandtoensureitssafetyandefficacyinvivoInadditiontolivercancer,miR-148bhasalsobeenidentifiedasapotentialtherapeutictargetinvariousothertypesofcancer,includingbreast,lung,andcoloncancer.However,thedeliveryofmiRNA-basedtherapiesremainschallengingduetotheirlowstabilityandpoorbioavailability.ResponsenanoscalegenevectorshavebeenshowntobeanefficientandversatileplatformforthedeliveryofmiRNA-basedtherapies,astheycanprotectthepayloadfromdegradationandenhanceitscellularuptakeandtargeting.

Moreover,responsenanoscalegenevectorscanbeeasilyfunctionalizedwithtargetingmoietiestoincreasetheirspecificitytowardscancercells.Forinstance,responsenanoscalegenevectorscanbedecoratedwithantibodiesorpeptidesthatrecognizeandbindtocellsurfacereceptorsthatareoverexpressedincancercellsbutnotinnormalcells.Thisway,responsenanoscalegenevectorscanselectivelydelivertherapeuticstocancercellswhilesparinghealthytissues,reducingtheriskofsideeffectsandtoxicity.

Importantly,nanomedicineapproachessuchasresponsenanoscalegenevectorshavethepotentialtoovercomethelimitationsofconventionalchemotherapyandradiotherapy,whichlackspecificityandoftencauseseveresideeffects.Byenablingtargeteddeliveryoftherapeutics,nanomedicineapproachescanenhancetheefficacyandsafetyofcancertreatment,ultimatelyimprovingpatients'qualityoflifeandsurvival.

Inconclusion,responsenanoscalegenevectorscarryingmiR-148brepresentapromisingtherapeuticstrategyforlivercancer,astheycanefficientlyinhibitcancercellinvasionandmetastasis.However,furtherresearchisneededtooptimizethedesignandformulationofnanovectorsformiRNAdelivery,andtoevaluatetheirsafetyandefficacyinpreclinicalandclinicalstudies.Withcontinuedefforts,nanomedicineapproacheshavethepotentialtorevolutionizecancertreatmentandimprovepatientoutcomesInadditiontolivercancer,nanomedicineapproacheshaveshownpromisingresultsforthetreatmentofothertypesofcancer,includingbreastcancer,lungcancer,andpancreaticcancer.Forexample,targetednanoparticlescarryinganticancerdrugshavebeendevelopedthatcanselectivelybindtocancercellsandreleasetheircargo,resultinginreducedtoxicityandenhancedefficacy.Inaddition,nanovectorscanbedesignedtotargetspecificsignalingpathwaysandbiomoleculesthatareinvolvedincancerprogression,suchasEGFRandVEGF.

Anotherareaofactiveresearchinnanomedicineistheuseofnanoparticlesforcancerimaginganddiagnosis.Nanoparticle-basedcontrastagents,suchasironoxidenanoparticlesandquantumdots,havebeendevelopedformagneticresonanceimaging(MRI)andfluorescenceimaging,respectively.Thesecontrastagentscanimprovethesensitivityandspecificityofcancerdetection,andcanalsobeusedformonitoringtreatmentresponse.

Despitethepotentialbenefitsofnanomedicineforcancertherapyanddiagnosis,therearestillchallengesthatneedtobeaddressed.Oneofthemajorchallengesisthedevelopmentofsafeandeffectivenanovectorsforclinicaluse.Nanoparticlescanaccumulateinorganssuchastheliverandspleen,andmayalsotriggerimmuneresponsesandcausetoxicity.Therefore,itisimportanttocarefullyevaluatethesafetyandefficacyofnanovectorsinpreclinicalandclinicalstudies.

Inaddition,thereisaneedforbetterunderstandingoftheunderlyingmechanismsofnanoparticle-cellinteractionsandtheireffectsoncellularfunctions.Thisincludesinvestigatingthepathwaysofnanoparticleuptake,intracellulartrafficking,andcargorelease,aswellastheimmuneresponseselicitedbynanoparticles.

Furthermore,thetranslationofnanomedicinefrombenchtobedsiderequiresthedevelopmentofrobustmanufacturingprocessesandqualitycontrolmeasuresfornanovectors.Thisisnecessarytoensureconsistencyandreproducibilityofthenanoparticles,whichiscriticalforthesuccessofclinicaltrialsandcommercialization.

Inconclusion,nanomedicineapproachesholdgreatpromiseforthetreatmentanddiagnosisofcancer.Advancesinnanovectordesign,formulation,andcharacterizationhaveenabledthedevelopm